How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company earned $63.27 million during the quarter, compared to the consensus estimate of $63.72 million. The company's revenue for the quarter was down 37.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.08 EPS.

What other stocks do shareholders of Depomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) , Vertex Pharmaceuticals (VRTX) , MercadoLibre (MELI) , Alphabet (GOOG) , Horizon Therapeutics Public (HZNP) , Bausch Health Companies (BHC) , Gilead Sciences (GILD) , Allergan (AGN) and Bristol-Myers Squibb (BMY) .

NASDAQ:DEPO

Depomed (DEPO) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free DEPO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $7.09
▼
$7.42
50-Day Range: N/A
52-Week Range: $4.31
▼
$9.48

Volume: 940,193 shs
Average Volume: 1.30 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Depomed alerts:

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About Depomed Stock (NASDAQ:DEPO)

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

DEPO Stock News Headlines

October 30, 2023 | finance.yahoo.com

Vulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030

August 29, 2023 | thestreet.com

Horizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion Bid

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

August 13, 2023 | thestreet.com

Why DepoMed (DEPO) Stock Is Gaining Today

July 31, 2023 | finance.yahoo.com

Surge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028

July 8, 2023 | thestreet.com

Opioid Litigants Get Boost From Senate Report

May 17, 2023 | marketwatch.com

Chronic Fatigue Syndrome Therapeutics Drug Market Till 2030

May 12, 2023 | marketwatch.com

Pain Management Market Size, Outlook, Trends, Share by 2030

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

May 11, 2023 | marketwatch.com

Global Neuropathy Pain Treatment Market [2023] | Industry Set to Expand with Strong 3.4% CAGR and Reach USD 10560 Million by 2030

May 10, 2023 | msn.com

How Turkey's opposition is taking the taboo out of the headscarf debate

April 29, 2023 | marketwatch.com

Global Gabapentin Market by Size, Scope 2023: with Development Status 2031

April 23, 2023 | marketwatch.com

2023-2030 Chronic Pain Management Drugs Market Size with Manufactures and Upcoming Opportunities

April 17, 2023 | thestreet.com

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

April 15, 2023 | marketwatch.com

Peripheral Neuritis Treatment research report leads towards the developing of this industry with an estimated CAGR 11.1% during 2023-2030

April 13, 2023 | marketwatch.com

Neuropathy Pain Treatment Market Growth Prediction and Segment Insight 2023-2107

April 5, 2023 | marketwatch.com

Neuropathy Pain Treatment Market 2023 Size and Forecast to 2031

March 30, 2023 | marketwatch.com

Vulvodynia Treatment Market: Overview of the Regional Outlook 2023-2030

March 14, 2023 | marketwatch.com

Pain Management Market Size, Growth | Soaring Demand | 2023 - 2029

March 13, 2023 | marketwatch.com

Pain Relief Medications Market Research Report 2023-2028 with Top Countries Data

February 21, 2023 | marketwatch.com

Diabetic Neuropathy Treatment Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028

February 3, 2023 | marketwatch.com

Controlled Release Drug Delivery Market 2023 Expected to Reach Significant Rate by 2029

January 29, 2023 | marketwatch.com

Neuropathy Pain Treatment Market Growth, Size, Share, Opportunities, Industry Analysis and Forecast 2023 To 2028

January 23, 2023 | thestreet.com

CFO Says Depomed to Buy or Be Sold

January 3, 2023 | marketwatch.com

Neuropathic Pain Management Market Size, Share and Forecast 2028 with Top Countries Data

October 15, 2022 | newsweek.com

J.D. Vance Cancels Fundraiser Planned by Doctor Mentioned in Opioid Lawsuit - Newsweek

October 12, 2022 | marketwatch.com

Pain Management Drugs Market is Growing Worldwide | 133 Report Pages

See More Headlines

Receive DEPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/08/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:DEPO
CUSIP: 24990810
CIK: 1005201
Web: www.depomedinc.com
Phone: (224) 419-7106
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Daniel A. Peisert
President, Chief Executive Officer & Director
Paul Schwichtenberg
Chief Financial Officer & Senior Vice President
Ajay Patel
Chief Accounting Officer & Senior Vice President
Megan C. Timmins
Secretary, Senior Vice President & General Counsel
Max Nemmers
Head-Investor Relations & Administration

Key Competitors

View All Competitors

DEPO Stock Analysis - Frequently Asked Questions

How were Depomed's earnings last quarter?: Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company earned $63.27 million during the quarter, compared to the consensus estimate of $63.72 million. The company's revenue for the quarter was down 37.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.08 EPS.
What other stocks do shareholders of Depomed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Vertex Pharmaceuticals (VRTX), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP), Bausch Health Companies (BHC), Gilead Sciences (GILD), Allergan (AGN) and Bristol-Myers Squibb (BMY).

This page (NASDAQ:DEPO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Depomed (DEPO) Stock Price, News & Analysis

About Depomed Stock (NASDAQ:DEPO)

DEPO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

DEPO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info